Page 146 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 146
Chapter 6a
Supplemental Table 3. Diagnostic and prognostic measures for aaIPI, baseline MTV, for different cutoff values of the Deauville 5-point scale at I-PET4, and ∆SUVmax for 2-year PFS for subset of patients with baseline MTV analysis (n=296).
(95%CI) P-value AUC Prognostic information Discrimination Univariate Hazard Ratio (95%CI)
(0·57-0·62) (0·61-0·67) (0·60-0·70) (0·55-0·67) (0·48-0·59) (0·52-0·65) (0·55-0·67) <0·0001 0·64 <0·0001 0·59 <0·0001 0·65 0·0014 0·61 0·252 0·54 0·0161 0·58 0·0013 0·61
(91·9-97·4) (4·30-12·95) (95·7-99·3) (5·00-18·01) (43·5-56·1) (1·13-3·38) (25·7-37·4) (0·78-2·59) (38·5-51·2) (1·50-5·34) (77·4-87·0) (2·39-6·66) (51·9-64·3) (1·40-4·07) 95·4 7·46 31·2 1·42 49·8 1·96 44·7 2·83 98·3 9·49 82·7 3·99 58·2 2·39
18 Abbreviations: 95%CI= 95% confidence interval; AaIPI= age-adjusted international prognostic index; AUC= area under the receiver operating curve; DS= Deauville 5-point scale; ∆SUVmax= reduction of maximum standardized uptake value between baseline and interim F-FDG PET(/CT); H=high risk group; HI= high-intermediate risk group; I-PET= F-FDG PET(/CT) after four cycles; MTV= metabolic tumor volume; PFS= progression-free survival. 18
interim
Specificity %(95%CI)
Sensitivity %(95%CI)
(45·5-78·1) (21·7-44·9) (19·2-32·4) (55·1-78·3) (16·6-27·7) (64·0-85·3) (20·5-33·3) (67·7-88·0) (50·5-89·8) (12·0-32·3) (30·6-53·1) (36·8-61·6) (20·9-35·8) (51·7-75·4) Predictive Value %(95%CI) Positive 63·3 32·2 21·6 76·3 25·2 67·8 26·4 79·7 75·0 20·3 41·4 49·2 27·7 64·4 Diagnostic information Predictive Value Negative %(95%CI) (83·1-94·1) (79·4-90·9) (75·1-90·7) (80·7-91·2) (81·7-90·5) (78·4-87·1) (80·2-88·8) 85·0
84·1
86·1
89·8
83·2
86·7
86·8
Number of patients (n)
118 vs 178
L/LI vs HI/H
137 vs 159
88 vs 208
159 vs 137
226 vs 70
280 vs 16
266 vs 30
≤345ml vs >345ml
DS1 vs DS2-5
DS1-2 vs DS3-5
DS1-3 vs DS4-5
DS1-4 vs DS5
>70% vs ≤70%
∆SUVmax
144
AaIPI
Baseline
MTV
I-PET4
